

# Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)], By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2024

<https://marketpublishers.com/r/IA8465A454EEN.html>

Date: October 2020

Pages: 195

Price: US\$ 3,000.00 (Single User License)

ID: IA8465A454EEN

## Abstracts

Immuno-oncology is a unique approach that uses the body's immune system to fight cancer. These therapies activate an individual's immune system, making it able to recognize cancer cells and destroy them. Immuno-oncology therapies provide long lasting anti-cancer benefits to patients who previously had very few treatment options available to them. These therapies work against a large number of cancer types. The technological advancements are helping the growth of immuno-oncology market. The biotechnology and pharmaceutical companies are striving to launch new and most effective therapies.

According to the report "Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)], By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2024", the global immuno-oncology market is anticipated to reach US\$ 135 Billion by 2024. The report provides a detailed analysis of the global immuno-oncology market. The report also provides the current and forecasted market for immuno-oncology.

Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immuno-oncology market. Moreover, the report provides the sales of major marketed immuno-oncology drugs.

The global immuno-oncology market has been segmented on the basis of type of product into monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2019 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme pro-drug therapy and radio immunotherapy).

The report also sheds light on the geographic segmentation of the global immuno-oncology market. In 2019, North America was estimated to account for the largest share. Presence of major players, increased awareness and better distribution mechanisms are some of the prominent factors that have led to North America being the market leader.

On the basis of type of cancer, the immuno-oncology market is dominated by Lung Cancer with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2024.

A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immuno-oncology programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

The later part of the report discusses some of the prominent players in the global immuno-oncology market. Market share analysis of major players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immuno-oncology is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.

## Contents

### 1. ANALYST VIEW

### 2. RESEARCH METHODOLOGY

### 3. IMMUNO-ONCOLOGY: OVERVIEW

### 4. MARKET DYNAMICS

#### 4.1 Drivers

- 4.1.1 Increasing Cancer Incidences
- 4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
- 4.1.3 Growing Geriatric Population
- 4.1.4 High Healthcare Spending in Developed Economies
- 4.1.5 Strong Pipeline
- 4.1.6 Increasing Efficacy in a Wide Variety of Indications
- 4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products

#### 4.2 Challenges

- 4.2.1 Patent Expiry of Top-Selling Drugs
- 4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatments
- 4.2.3 Sky-High Development Costs of Cancer Immunotherapies
- 4.2.4 High Cost of Treatment
- 4.2.5 Lack of Awareness

#### 4.3 Opportunities

- 4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity
- 4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival
- 4.3.3 CAR-T Therapies: The Future of Cancer Care
- 4.3.4 Small Companies Offering Huge Opportunitites for Next Generation

#### Immunotherapies

### 5. GLOBAL IMMUNO-ONCOLOGY MARKET OUTLOOK 2024

### 6. GLOBAL IMMUNO-ONCOLOGY MARKET, BY PRODUCT CLASS

#### 6.1 Monoclonal Antibodies (mAbs)

- 6.1.1 Naked Monoclonal Antibodies
  - 6.1.1.1 Rituxan (Rituximab)
  - 6.1.1.2 Avastin (Bevacizumab)

- 6.1.1.3 Herceptin (Trastuzumab)
- 6.1.2 Conjugated Monoclonal Antibodies
  - 6.1.2.1 ADCETRIS (Brentuximab vedotin)
  - 6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1)
- 6.1.3 Bispecific Monoclonal Antibodies
  - 6.1.3.1 Blincyto (Blinatumomab)
- 6.1.4 Others
- 6.2 Therapeutic Vaccines
  - 6.2.1 Provenge
- 6.3 Immune Checkpoint Inhibitors
  - 6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
    - 6.3.1.1 Yervoy (Ipilimumab)
  - 6.3.2 PD-1 and PD-L1 Inhibitors (Programmed Death 1 and Programmed Death Ligand)
    - 6.3.2.1 Opdivo (Nivolumab)
    - 6.3.2.2 Keytruda (Pembrolizumab)
- 6.4 Others

## **7. GLOBAL IMMUNO-ONCOLOGY MARKET, BY MAJOR INDICATIONS**

- 7.1 Head & Neck Cancer
- 7.2 Lung Cancer
- 7.3 Melanoma
- 7.4 Lymphoma
- 7.5 Leukemia
- 7.6 Others

## **8. GLOBAL IMMUNO-ONCOLOGY MARKET, BY GEOGRAPHY**

- 8.1 North America
- 8.2 Europe
- 8.3 Asia-Pacific

## **9. TRENDS & DEVELOPMENTS**

- 9.1 Lucrative Investment Trend
- 9.2 Emergence of Targeted and Combination Therapies
- 9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market

## **10. STRATEGIC COLLABORATIONS & ALLIANCES IN THE IMMUNO-ONCOLOGY**

## **INDUSTRY**

### **11. PIPELINE ANALYSIS OF IMMUNO-ONCOLOGY**

### **12. COMPETITIVE LANDSCAPE**

#### 12.1 Share of Major Players

### **13. KEY PLAYERS ANALYSIS**

#### 13.1 F. Hoffmann-La Roche AG

#### 13.2 Bristol-Myers Squibb

#### 13.3 Merck & Co., Inc.

#### 13.4 Novartis

#### 13.5 AstraZeneca Plc

#### 13.6 Pfizer Inc

#### 13.7 Eli Lilly and Company

#### 13.8 Johnson & Johnson

#### 13.9 Amgen Inc.

## List Of Figures

### LIST OF FIGURES:

- Figure 4-1: Global - Cancer Incidences (Million), 2020, 2025, 2030, 2035 & 2040
- Figure 4-2: Global - Cancer Mortality (Million) 2020, 2025, 2030, 2035 & 2040
- Figure 4-3: Global - Population above 65 Years (Billion), 2019 & 2050
- Figure 5-1: Global - Immuno-Oncology Market (Billion US\$), 2018-2024
- Figure 6-1: Global - Share of Immuno-Oncology Market by Product (%), 2019
- Figure 6-2: Global - Share of Immuno-Oncology Market by Product (%), 2024
- Figure 6-3: Global - Monoclonal Antibodies Market (Billion US\$), 2018-2024
- Figure 6-4: Global - Rituxan Market (Million US\$), 2016-2019
- Figure 6-5: Global - Avastin Market (Million US\$), 2016-2019
- Figure 6-6: Global - Herceptin Market (Million US\$), 2016-2019
- Figure 6-7: Global - ADCETRIS Market (Million US\$), 2016-2019
- Figure 6-8: Global - Kadcyla Market (Million US\$), 2016-2019
- Figure 6-9: Global - Blincyto Market (Million US\$), 2016-2019
- Figure 6-10: Global - Other Monoclonal Antibodies Market (Billion US\$), 2018-2024
- Figure 6-11: Global - Therapeutic Cancer Vaccines Market (Million US\$), 2018-2024
- Figure 6-12: Global - Provenge Market (Million US\$), 2016-2019
- Figure 6-13: Global - Immune Checkpoint Inhibitors Market (Billion US\$), 2018-2024
- Figure 6-14: Global - Yervoy Market (Million US\$), 2016-2019
- Figure 6-15: Global - Opdivo Market (Million US\$), 2016-2019
- Figure 6-16: Global - Keytruda Market (Million US\$), 2016-2019
- Figure 6-17: Global - Others Immuno-oncology Drugs Market (Billion US\$), 2018-2024
- Figure 7-1: Global - Share of Immuno-Oncology Market by Application (%), 2019
- Figure 7-2: Global - Share of Immuno-Oncology Market by Application (%), 2024
- Figure 7-3: Global - Head & Neck Cancer Market (Billion US\$), 2018-2024
- Figure 7-4: Head & Neck Cancer - Immunotherapy Clinical Studies by Product-class
- Figure 7-5: Head & Neck Cancer - Immunotherapy Clinical Studies by Phase
- Figure 7-6: Global - Lung Cancer Market (Billion US\$), 2018-2024
- Figure 7-7: Lung Cancer - Immunotherapy Clinical Studies by Product-class
- Figure 7-8: Lung Cancer - Immunotherapy Clinical Studies by Phase
- Figure 7-9: Global - Melanoma Market (Billion US\$), 2018-2024
- Figure 7-10: Melanoma - Immunotherapy Clinical Studies by Product-class
- Figure 7-11: Melanoma - Immunotherapy Clinical Studies by Phase
- Figure 7-12: Global - Lymphoma Market (Billion US\$), 2018-2024
- Figure 7-13: Lymphoma - Immunotherapy Clinical Studies by Product-class
- Figure 7-14: Lymphoma - Immunotherapy Clinical Studies by Phase

- Figure 7-15: Global - Leukemia Market (Billion US\$), 2018-2024
- Figure 7-16: Leukemia - Immunotherapy Clinical Studies by Product-class
- Figure 7-17: Leukemia - Immunotherapy Clinical Studies by Phase
- Figure 7-18: Global - Other Cancer Market (Billion US\$), 2018-2024
- Figure 7-19: Other Cancer - Immunotherapy Clinical Studies by Product-class
- Figure 7-20: Other Cancer - Immunotherapy Clinical Studies by Phase
- Figure 8-1: Global - Share of Immuno-Oncology Market by Geography (%), 2019
- Figure 8-2: Global - Share of Immuno-Oncology Market by Geography (%), 2024
- Figure 8-3: North America - Immuno-Oncology Market (Billion US\$), 2018-2024
- Figure 8-4: Europe - Immuno-Oncology Market (Billion US\$), 2018-2024
- Figure 8-5: Asia-Pacific - Immuno-Oncology Market (Billion US\$), 2018-2024
- Figure 11-1: Global - Immuno-Oncology Clinical Studies by Product-class
- Figure 11-2: Global - Immuno-Oncology Pipeline Analysis by Phase (%), 2019
- Figure 12-1: Global - Share of Key Players in Immuno-Oncology Market (%), 2019
- Figure 13-1: F. Hoffmann-La Roche AG - Revenue by Business Segment (%), 2019
- Figure 13-2: F. Hoffmann-La Roche AG - Pharmaceutical Division Revenue by Geography (%), 2019
- Figure 13-3: Bristol Myers Squibb - Revenue by Geography (%), 2019
- Figure 13-4: Merck & Co., Inc. - Revenue by Business Segment (%), 2019
- Figure 13-5: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segment (%), 2019
- Figure 13-6: Merck & Co., Inc. - Revenue by Geography (%), 2019
- Figure 13-7: Novartis - Revenue by Business Segment (%), 2019
- Figure 13-8: Novartis - Innovative Medicines Division Revenue by Segment (%), 2019
- Figure 13-9: Novartis - Pharmaceuticals Division Revenue by Segment (%), 2019
- Figure 13-10: Novartis - Revenue by Geography (%), 2019
- Figure 13-11: AstraZeneca Plc - Revenue by Business Segment (%), 2019
- Figure 13-12: AstraZeneca Plc - Revenue by Geography (%), 2019
- Figure 13-13: Pfizer Inc - Revenue by Business Segment (%), 2019
- Figure 13-14: Pfizer Inc - Revenue by Geography (%), 2019
- Figure 13-15: Eli Lilly and Company - Revenue by Business Segment (%), 2019
- Figure 13-16: Eli Lilly and Company - Human Pharmaceutical Division Revenue by Business Segment (%), 2019
- Figure 13-17: Eli Lilly and Company - Revenue by Geography (%), 2019
- Figure 13-18: Johnson & Johnson - Revenue by Business Segment (%), 2019
- Figure 13-19: Johnson & Johnson - Revenue by Pharmaceutical Segment (%), 2019
- Figure 13-20: Johnson & Johnson - Revenue by Geography (%), 2019
- Figure 13-21: Amgen Inc. - Revenue by Product (%), 2019
- Figure 13-22: Amgen Inc. - Revenue by Geography (%), 2019





## List Of Tables

### LIST OF TABLES:

- Table 4-1: Immuno-Oncology - Late Stage Research Pipeline
- Table 4-2: US & Europe - Major Drug Patent Expiry in Immuno-Oncology Market
- Table 6-1: Ongoing Trials for Rituxan
- Table 6-2: Ongoing Trials for Avastin
- Table 6-3: Ongoing Trials for Herceptin
- Table 6-4: Ongoing Trials for ADCETRIS
- Table 6-5: Ongoing Trials for Kadcyla
- Table 6-6: Ongoing Trials for Blincyto
- Table 6-7: Ongoing Trials for Provenge
- Table 6-8: Ongoing Trials for Yervoy
- Table 6-9: Ongoing Trials for Opdivo
- Table 6-10: Ongoing Trials for Keytruda
- Table 7-1: Global - Oncology Incidence by Geography ('000), 2020 & 2025
- Table 9-1: Selected Immuno-Oncology and/or Targeted Therapy Combinations
- Table 10-1: Strategic Collaborations in the Immuno-Oncology Industry
- Table 11-1: Global - Immuno-Oncology Product Pipeline
- Table 13-1: F. Hoffmann-La Roche AG - Key Financials (Billion US\$), 2017-2019
- Table 13-2: F. Hoffmann-La Roche AG - Commercialized Immuno-Oncology Products
- Table 13-3: F. Hoffmann-La Roche AG - Product Pipeline
- Table 13-4: Bristol Myers Squibb - Key Financials (Billion US\$), 2017-2019
- Table 13-5: Bristol Myers Squibb - Commercialized Immuno-Oncology Products
- Table 13-6: Bristol Myers Squibb - Product Pipeline
- Table 13-7: Merck & Co., Inc. - Key Financials (Billion US\$), 2017-2019
- Table 13-8: Merck & Co., Inc. - Commercialized Immuno-Oncology Products
- Table 13-9: Merck & Co., Inc. - Product Pipeline
- Table 13-10: Novartis - Key Financials (Billion US\$), 2017-2019
- Table 13-11: Novartis - Commercialized Immuno-Oncology Products
- Table 13-12: Novartis - Product Pipeline
- Table 13-13: AstraZeneca Plc - Key Financials (Billion US\$), 2017-2019
- Table 13-14: AstraZeneca Plc - Commercialized Immuno-Oncology Products
- Table 13-15: AstraZeneca Plc - Product Pipeline
- Table 13-16: Pfizer Inc - Key Financials (Billion US\$), 2017-2019
- Table 13-17: Pfizer Inc - Commercialized Immuno-Oncology Products
- Table 13-18: Pfizer Inc - Product Pipeline
- Table 13-19: Eli Lilly and Company - Key Financials (Billion US\$), 2017-2019

Table 13-20: Eli Lilly and Company - Commercialized Immuno-Oncology Products

Table 13-21: Eli Lilly and Company - Product Pipeline

Table 13-22: Johnson & Johnson - Key Financials (Billion US\$), 2017-2019

Table 13-23: Johnson & Johnson - Commercialized Immuno-Oncology Products

Table 13-24: Johnson & Johnson - Product Pipeline

Table 13-25: Amgen Inc. - Key Financials (Billion US\$), 2017-2019

Table 13-26: Amgen Inc. - Commercialized Immuno-Oncology Products

Table 13-27: Amgen Inc. - Product Pipeline

## I would like to order

Product name: Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)], By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2024

Product link: <https://marketpublishers.com/r/IA8465A454EEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IA8465A454EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970